CYLD Alterations Are Associated With Metastasis and Poor Prognosis in Human Papilloma Virus-Positive Head and Neck Cancer. Read more about CYLD Alterations Are Associated With Metastasis and Poor Prognosis in Human Papilloma Virus-Positive Head and Neck Cancer.
International guidelines for intratumoral and intranodal injection of NBTXR3 nanoparticles in head and neck cancers. Read more about International guidelines for intratumoral and intranodal injection of NBTXR3 nanoparticles in head and neck cancers.
Higher area deprivation index is associated with poorer local control and overall survival in non-metastatic nasopharyngeal carcinoma. Read more about Higher area deprivation index is associated with poorer local control and overall survival in non-metastatic nasopharyngeal carcinoma.
Rate of occult metastasis in lip squamous cell carcinoma: A systematic review and meta-analysis. Read more about Rate of occult metastasis in lip squamous cell carcinoma: A systematic review and meta-analysis.
The tumor microenvironment of benign and malignant salivary gland tumors. Read more about The tumor microenvironment of benign and malignant salivary gland tumors.
Postoperative inpatient surgical complications following head and neck microvascular free tissue transfer. Read more about Postoperative inpatient surgical complications following head and neck microvascular free tissue transfer.
Prognostic risk factors of buccal squamous cell carcinoma: A case-control study. Read more about Prognostic risk factors of buccal squamous cell carcinoma: A case-control study.
A supervised machine learning model for identifying predictive factors for recommending head and neck cancer surgery. Read more about A supervised machine learning model for identifying predictive factors for recommending head and neck cancer surgery.
Carboplatin and paclitaxel after anti-PD-1 or anti-PD-L1 antibody therapy in recurrent and/or metastatic squamous cell carcinoma of head and neck. Read more about Carboplatin and paclitaxel after anti-PD-1 or anti-PD-L1 antibody therapy in recurrent and/or metastatic squamous cell carcinoma of head and neck.
Elective management of the N0 neck in maxillary sinus squamous cell carcinoma. Read more about Elective management of the N0 neck in maxillary sinus squamous cell carcinoma.
